BioAge Labs, Inc. BIOA R2KR3KPHARMA
Company Overview
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +1.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 1.60% |
Stock Price Performance
| 1 Year: | +110.31% |
| 6 Months: | -52.74% |
| 3 Months: | -38.92% |
| 1 Month: | -14.91% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross2d ago
- RSI (14)34.42 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 61.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BIOA BioAge Labs, Inc. R2KR3KPHARMA | 9.59 | -4.01 | $440.15M | 0.00% | -33.77% | -28.21% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 0 | 1.45M | 2.41M | 2.05M | 2.77M | 2.45M |
| Operating Income | - | - | -9.89M | -12.81M | -15.27M | -24.75M | -16.45M | -24.77M | -23.14M | -25.38M | -29.33M |
| Net Income | -11.08M | -17.19M | -14.62M | -12.99M | -13.58M | -23.41M | -12.93M | -21.56M | -20.17M | -22.25M | -26.10M |
| Diluted EPS | - | - | -8.74 | -7.76 | -7.94 | -6.70 | -0.36 | -0.60 | -0.56 | -0.52 | -0.58 |
| R&D Expense | - | - | 6.53M | 9.32M | 10.47M | 20.02M | 11.11M | 19.84M | 18.51M | 20.41M | 24.36M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | - | 0 | 8.99M |
| Operating Income | -48.40M | -78.19M | -92.78M |
| Net Income | -63.85M | -71.11M | -80.61M |
| Diluted EPS | -38.17 | -6.63 | -2.24 |
| R&D Expense | 33.89M | 59.04M | 73.97M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 28.43M | 25.92M | 358.23M | 294.89M |
| Current Assets | 28.03M | 25.31M | 357.10M | 286.79M |
| Cash & Equivalents | 27.64M | 21.64M | 354.35M | 188.89M |
| Inventory | - | - | - | - |
| Receivables | - | - | 0 | 769.00K |
| Total Liabilities | 140.99M | 199.32M | 35.11M | 22.84M |
| Current Liabilities | 5.86M | 58.17M | 27.77M | 20.14M |
| Long Term Debt | 2.25M | 8.20M | 2.50M | - |
| Total Debt | 2.47M | 53.25M | 8.70M | 5.56M |
| Total Equity | -112.56M | -173.40M | 323.13M | 272.05M |
| Shares Outstanding | 34.17M | 34.17M | 35.85M | 37.39M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -37.36M | -51.52M | -81.63M |
| Investing Cash Flow | -266.00K | -366.00K | -95.22M |
| Financing Cash Flow | 34.94M | 381.20M | 11.47M |
| Capital Expenditure | -166.00K | -366.00K | -719.00K |
| Free Cash Flow | -37.53M | -51.89M | -82.35M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | -1,031.5% |
| Net Margin % | - | - | -896.1% |
| ROE % | 36.8% | -22.0% | -29.6% |
| ROCE % | 150.1% | -23.7% | -33.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | a16z Capital Management, L.L.C. | 7.04% | 3.23M | $31.20M |
| 2 | Blackrock Inc. | 6.21% | 2.85M | $27.49M |
| 3 | Cormorant Asset Management, LP | 5.21% | 2.39M | $23.07M |
| 4 | Sofinnova Investments, Inc. | 5.00% | 2.29M | $22.14M |
| 5 | Jupiter Topco LLC | 4.67% | 2.14M | $20.70M |
| 6 | Octagon Capital Advisors LP | 3.81% | 1.75M | $16.87M |
| 7 | RA Capital Management, L.P. | 3.64% | 1.67M | $16.13M |
| 8 | MPM Bioimpact LLC | 3.63% | 1.67M | $16.09M |
| 9 | Vanguard Capital Management LLC | 3.36% | 1.54M | $14.90M |
| 10 | Polar Capital Holdings PLC | 2.34% | 1.07M | $10.35M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BIOA
BioAge: CV Risk Data Due H2 A Major Catalyst After Rival's Data Causes Sell-Off (BIOA) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPXy1ad3E4eHduZ2NFNWJiMUE0QTV1THlzeS13UlZoajZBSG41S2xGRVIzeW42OXY4QmNES1ZuM0gwZTl4cFdQRWMwMnJaNkVHTHo3dGMyX2d4SFlGcERDTWZVQVdZc1dsRHN4OEw5V1JOc3hvNmxScUxBellHZnBEbzBxYThxRWxxOTZJYn…
The Technical Signals Behind (BIOA) That Institutions Follow - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQVGR1dmRydUxCQTdsTzlxMFJMOTY0YkU3YmFkQlIwRmFOREY2R2MtQ1pfNjV0c0FyVzFyNHhNME9ZVHJHQVBCZ0xDZ0V6U2ZieTk0SWxVMzl6T0xHQl9MaEZxaE9wLUN0UmJ3RW5XTTd0Q2hScHhpWWZNdXRwMnh1YXdaeExydm9QaU9ZWU…
Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNbnE4RUI3YzhkV1RkSkprZ2hoR2lYWE9fUkhIQkxSNEk0b0FucjZ4bUtlSVJqOW0wT0ZBZmFHZDZQbUlGNjY0LW4xXzZJdGFXNDBManMyWjlTTUU4WTJNU0xGNEppa0pTWVpzd2pYY18yX1ZFQUVfSmlMY3YwVU1tMHY0SUl3RlZtUkZBNU…
Why is BioAge Labs stock plunging today? - Investing.com
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPd2ViN1AwcUJrWHFYV21icVJMaFVmQktQdVF6Z2JOcVhNTVp2M2h6Y2U4VDJJd3BFODFRenBJeVJ1THg1NnlMUWV0dDNZOFZkWWVpbEdRQnFfeENoVEdvXzdIRjk3bTNUbzhMcTVrZHRSQUZQZy1MZEM3TXl0M1YtODVJcFNtOElEcWJWX1…
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQcllscXNiRzFDbldMMW5uVU5xRGZVUzlRNHQzSzFkWmVPcmRGS1FTRXBqa1NGVDVHVDgzeUNvMF82cnpxMV9WbkI1MWtGVlVVeUtGUnIxa0x1WmhJWWFlUGdheldFWlQzdjA5RXZuM2JjcF9BTUgyTHJTTTI5VEE1TDRhZzVsVWRUSGhLSl…
BIOA Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9MNDJVTTA2d0FiZGJYdUdfUHZvWWJHdzBMbWZDdktqTGxUZFRJcE9ndTZMOHc1MVJjaVhaSThScVdKc2ppb3B6MmtRSTkwcEg2QmxSaF9wVTFLSUVEaEMxc3UwZzI1OFpWZEdDZHZqMEJackRMUDFOYTBn?oc=5" target="_blank">BIO…
BIOA — Frequently Asked Questions
What is the current share price of BioAge Labs, Inc. (BIOA)?
As of 2026-09-07 16:24 PDT, BioAge Labs, Inc. (BIOA) trades at $9.59 on NasdaqGS. Its 52-week range is $4.42 to $25.10.
What is the market capitalisation of BIOA?
BioAge Labs, Inc. (BIOA) has a market capitalisation of $440.15M on NasdaqGS.
What is the P/E ratio of BIOA?
BIOA trades at a trailing price-to-earnings (P/E) ratio of -4.01. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.37.
What is the return on equity (ROE) of BIOA?
BIOA has a return on equity (ROE) of -28.21%. Its return on capital employed (ROCE) is -33.77%.
Is BIOA a good stock to buy?
This page provides a data-driven analysis of BioAge Labs, Inc. (BIOA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.